Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Psychedelic State(s) of America
Politics5 min read

VA Pitches Psychedelic Readiness to Congress as Staffing Losses, FDA Vacuum and a Democratic Takeover Loom

VA officials told a House panel 180,000 veterans could qualify on day one, but rollout capacity will be far smaller as the department sheds staff and the FDA goes without a leader.

By Jack Gorsline

Contributor ·

VA Pitches Psychedelic Readiness to Congress as Staffing Losses, FDA Vacuum and a Democratic Takeover Loom

Fuel the Future of Psychedelic Journalism

Want to financially support original, independent reporting like this? You can! Donate at the link below.

Donate to PSA

NEWS

PSA News: VA Pitches Psychedelic Readiness to Congress as Staffing Losses, FDA Vacuum and a Democratic Takeover Loom

WASHINGTON — U.S. Department of Veterans Affairs officials told congressional lawmakers Wednesday that the department is preparing to become the nation's first healthcare system to deliver FDA-approved psychedelic-assisted therapies, even as officials conceded that initial rollout capacity will likely be measured in thousands rather than the millions touted by advocates.

At a Nov. 18 hearing before the House Veterans’ Affairs Subcommittee on Health titled "Psychedelic-Assisted Therapies for Veterans: The Path Forward," Chairwoman Mariannette Miller‑Meeks, R‑Iowa, highlighted VA data citing an average of 17 veteran suicides per day in 2024 before raising the central question: "Will the VA be ready?" The session marked the final panel co-led by Miller‑Meeks and Ranking Member Julia Brownley, D‑Calif., who noted it was her final hearing on the subcommittee.

The VA’s readiness push came during a turbulent week across federal health policy. Just a day prior, the White House abruptly withdrew Dr. Heidi Overton's nomination to lead the Food and Drug Administration, leaving the agency without a confirmed chief ahead of January's Democratic shift in Congress. Meanwhile, ARPA-H committed up to $4.9 million over five years to Mark Cuban’s Cost Plus Drug Co. to advance ibogaine research, even as a ProPublica investigation highlighted widespread clinical staffing shortages throughout the VA system.

On the first panel, VA officials Andrew Gradison and Dr. Ilse Wiechers detailed an operational roadmap. A second panel of outside experts followed: Dr. Leith States, Dr. Marion Coe, Dr. Mark Niciu, and Dr. Raquel Halfond. Gradison emphasized that the VA intends to be "the first healthcare system in the nation" to administer psychedelic therapies once approved, citing 21 active VA studies, a psilocybin trial launched Aug. 5 for major depressive disorder, and interagency agreements with HHS and the FDA under Executive Order 14401.

Andrew Gradison and Dr. Ilse Wiechers of the Veterans Health Administration testify before the House Veterans' Affairs Subcommittee on Health
Andrew Gradison and Dr. Ilse Wiechers of the Veterans Health Administration testify before the House Veterans’ Affairs Subcommittee on Health on Nov. 18, 2026. (Photo: C‑SPAN)

Gradison confirmed that 10 Phase I rollout sites have been selected nationwide but declined to disclose them publicly, agreeing to provide the list and a 30-day staffing plan directly to Rep. Maggie Goodlander, D‑N.H. He noted that treatments cannot begin until clearing FDA approval, Drug Enforcement Administration rescheduling, and state-level regulatory steps. Wiechers stressed that clinician training must include experiential, supervised components, remarking, "we don't want anyone flying blind." Despite the planned expansion, Gradison stated that the VA is not requesting dedicated funding for psychedelic therapies in fiscal year 2027, maintaining that existing resources are sufficient.

The hearing highlighted the gap between broad public rhetoric and internal VA capacity constraints. Gradison testified that approximately 2.1 million veterans carry a qualifying diagnosis; applying standard clinical trial criteria (~6.2%) yields an estimated 180,000 eligible veterans on day one. This marked an increase from the 100,000 figure he cited at the Horizons conference on Oct. 15, where he acknowledged that treating even four-digit numbers in year one would be challenging and warned that demand will outpace supply.

Democratic lawmakers focused on the bottleneck. Goodlander observed that treating 10,000 veterans would reach fewer than 1 in 18 eligible patients (and treating 1,000 would cover just 1 in 180), asking, "Who goes first and who decides?" Dr. States pointed out that roughly half of all veterans are not enrolled in VA care, making an internal rollout "only getting to a 50% solution." Wiechers also urged realistic expectations regarding long-term cost savings, noting a lack of longitudinal data on symptom remission durability.

Outside experts warned that clinical infrastructure, rather than drug efficacy, poses the steepest hurdle. "The central challenge is not simply whether these medications can work," said Dr. Marion Coe of PinneyAssociates. "It is whether we can build the infrastructure to deliver them safely to the people who need them the most."

Lawmakers pressed officials on building clinical capacity amid ongoing workforce losses. A Nov. 11 ProPublica report revealed a 3.4% drop in mission-critical staff (about 5,100 positions), while an internal watchdog report showed 97% of VA hospitals reporting severe physician shortages. Rep. Herb Conaway, D‑N.J., cited 23,620 staff departures between January 2025 and July 2026, while Goodlander and Halfond pointed to hundreds of lost psychologist and psychiatrist positions. Brownley described VA leadership’s staffing posture as "totally at odds" with a rapid clinical rollout, though Wiechers insisted the agency is actively recruiting and enhancing care efficiency.

States warned that relying on external community care networks presents risks, emphasizing that "a referral cannot become a transfer of accountability." Meanwhile, Senate fiscal year 2027 appropriations bills released Nov. 10 contained research directives without granting new funding.

The subcommittee also evaluated federal developments around ibogaine. On Nov. 12, ARPA-H announced up to $4.9 million over five years for Mark Cuban’s Cost Plus Drug Co. to establish domestic manufacturing for clinical trials, utilizing patient data from Beond, an ibogaine clinic in Cancún, Mexico. Gradison confirmed that Beond’s data from over 2,000 patients will be accessible to the VA, even as federal agencies remain cautious regarding cardiotoxicity risks and manufacturing constraints. States noted that the FDA’s request for information on ibogaine closes Nov. 20.

Addressing foreign treatment, Gradison stated firmly that the VA does not support veterans traveling abroad for care. However, clinicians operating internationally advocated for applying practical lessons to U.S. frameworks. "At The Mission Within, years of caring for veterans have taught us how much of the work happens before and after ibogaine treatment," said Dr. Martín Polanco, founder and medical director of the program. "That includes careful cardiac screening, training teams to recognize and respond to complications, and making sure veterans have follow-up care when they go home."

Regulatory uncertainty at the FDA further complicates implementation. Developers Compass Pathways and Usona Institute are advancing psilocybin candidates toward federal review. Following the White House's withdrawal of Overton's nomination a day before a planned Senate committee vote, the FDA could go up to two years without a confirmed leader, though analysts anticipate minimal day-to-day disruption.

How the incoming 120th Congress will navigate psychedelic policy remains an open question. Bipartisan advocates expect continued cross-party support through initiatives like the Congressional PATH Caucus. However, Democratic lawmakers are expected to push aggressively on VA staffing, informed consent, and community care guardrails once taking control in January.

"Psychedelic policy reform has always enjoyed broad bipartisan support, and I don't expect that to change," said Logan Davidson, policy director at Veterans Exploring Treatment Solutions (VETS). "This Congress gives the field a real opportunity to focus and unite behind key efforts."

For lawmakers on Capitol Hill, however, the immediate measure of success remained grounded in patient safety rather than speed. "If you mess up this much, this goes away forever," Rep. Morgan Luttrell, R‑Texas, warned during the hearing. "If you save one veteran, you have succeeded. One. That's it."

If you or someone you know is struggling, call or text 988 in the U.S. to reach the Suicide & Crisis Lifeline.


Enjoyed this story? Subscribe to Psychedelic State(s) of America and share this post with someone who should read it.

Support independent journalism

The PSA Media Fund

Psychedelic State(s) of America isn’t another news outlet — it’s a vessel to help the fantastic independent psychedelic and cannabis media organizations that already exist do more of what they do best. Our coverage is reader-funded, and your support keeps news, commentary, and education on psychedelic policy free for everyone.

Donate to PSA

Until next time,
The Psychedelic State(s) of America Team

Read our Editorial StandardsRequest a correction

You read to the end

Get PSA News & Investigations in your inbox

Free to read. Free to subscribe.

About the author

Jack Gorsline

Contributor

Jack Gorsline is a Washington, D.C.-based investigative reporter covering the politics of drug policy reform - with a focus on psychedelics and cannabis legalization advocacy both in the United States and around the world. Jack’s reporting has been published by the Boston Institute for Nonprofit Journalism (BINJ), Talking Joints Memo, DoubleBlind Magazine, Filter Magazine, Marijuana Moment, Psychedelic Alpha, Lucid News, Cannabis & Tech Today, Reality Sandwich, High Times Magazine, and featured by Psychedelics Today, Ecstatic Integration, and The Mycopreneur Podcast, GBH Radio, The Microdose from UC’s Berkeley Center for the Science of Psychedelics, among others. Jack is also the founder of both Psychedelic State(s) of America and The Psychedelic Writers Guild (PWG) - a new nonprofit sponsored community building-oriented, collaborative media project being created in partnership with a diverse coalition of psychedelic scientists, journalists, medical practitioners, legal professionals, political advocates, and community leaders from around the world. You can find Jack on Twitter @JackGorsline, Instagram @Jack.Gorsline, Linkedin, Substack, Bluesky, and more!

Related stories

Picked by shared tags, desk, and byline.